Semapimod (tetrahydrochloride)

Semapimod (tetrahydrochloride)

• CAS Number: 164301-51-3
• UNSPSC Description: Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6. Semapimod tetrahydrochloride inhibits TLR4 signaling (IC50≈0.3 μM). Semapimod tetrahydrochloride inhibits p38 MAPK and nitric oxide production in macrophages. Semapimod tetrahydrochloride has potential in a variety of inflammatory and autoimmune disorders[1][2][3].
• Target Antigen: Interleukin Related; p38 MAPK; TNF Receptor
• Type: Reference compound
• Related Pathways: Apoptosis;Immunology/Inflammation;MAPK/ERK Pathway
• Applications: COVID-19-immunoregulation
• Field of Research: Cancer; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/semapimod-tetrahydrochloride.html
• Solubility: H2O : 2.17 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: O=C(NC1=CC(/C(C)=N/NC(N)=N)=CC(/C(C)=N/NC(N)=N)=C1)CCCCCCCCC(NC2=CC(/C(C)=N/NC(N)=N)=CC(/C(C)=N/NC(N)=N)=C2)=O.Cl.Cl.Cl.Cl
• Molecular Weight: 890.74
• References & Citations: [1]Wehner S, Set al. Inhibition of p38 mitogen-activated protein kinase pathway as prophylaxis of postoperative ileus in mice. Gastroenterology. 2009;136(2):619‐629.|[2]Nishimatsu H, et al. Blockade of endogenous proinflammatory cytokines ameliorates endothelial dysfunction in obese Zucker rats. Hypertens Res. 2008;31(4):737‐743.|[3]Wang J, et al. Experimental Anti-Inflammatory Drug Semapimod Inhibits TLR Signaling by Targeting the TLR Chaperone gp96. J Immunol. 2016;196(12):5130‐5137.|[4]Miller IS, et al. Semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia. PLoS One. 2014 May 9;9(5):e95885.
• Shipping Conditions: Blue Ice
• Clinical Information: Phase 2